Abstract 345P
Background
Breast cancer surgery can impair shoulder function, and the effects of rehabilitation exercise during early recovery remain uncertain. This study aims to assess the effectiveness of tailored exercise intervention on shoulder function recovery at one and six months post-surgery.
Methods
A total of 122 breast cancer patients (Stage 0-3) scheduled for surgery were evaluated, and 58 patients (mean age 50.2±6.6 years) were randomly assigned to an exercise or usual care group (1:1). The exercise group underwent five tailored exercise education sessions, starting one day before hospital discharge and continuing for four weeks after surgery. Participants received exercise diaries, online links, and QR codes for home-based workouts. The primary outcome measured the proportion of participants achieving 90% of their pre-surgery shoulder ROM and strength at one and six months post-surgery. Secondary measures included DASH and SPADI scores, physical activity levels, and body composition.
Results
Out of 58 participants, 56 (96.6%) completed the trial, with a 96.6% exercise compliance rate one month after surgery. In the exercise group, 92.9% and 96.2% achieved pre-surgery shoulder strength levels at one and six months post-surgery, respectively, compared to 3.7% and 32.1% in the control group. The exercise group also exhibited significantly lower shoulder pain and disability scores (SPADI) at one and six months after surgery, as well as higher physical activity levels at six months. Table: 345P
Change in shoulder strength among postoperative breast cancer patients
Affected arm | |||
EPET (n=25) | Usual Care (n=26) | p | |
Sum of strength (Ib) | |||
T0 | 44.1±10.2 | 47.5±11.1 | 0.36 |
T1 | 23.2±10.3∗∗∗ | 23.8±9.4∗∗∗ | 0.80 |
T2 | 40.4±11.9 | 28.5±11.9∗∗∗ | 0.001 |
T3 | 45.9±14.7 | 32.0±11.2∗∗∗ | <0.001 |
T4 | 51.3±14.0 | 32.0±9.2∗∗∗ | <0.001 |
T5 | 61.0±17.1∗∗∗ | 38.3±8.4∗∗∗ | <0.001 |
Mean±SD, P=represented the results of independent T-test (the p-value adjusted for Bonferroni method (0.05/6=0.0083), *=represented paired t-test [**p<0.01 vs. baseline, ***p<0.001 vs. baseline (p-value adjusted for Bonferroni method)] Abbreviation: early postoperative exercise therapy; EPET
.Conclusions
Early implementation of tailored exercise during rehabilitation significantly improved shoulder function beyond pre-surgery levels. This study provides essential insights into the efficacy and safety of early rehabilitation exercises for breast cancer patients during the post-surgery recovery phase.
Clinical trial identification
The Institutional Ethics Review Board of Severance Hospital and WHO International Clinical Trials Registry Platform (ICTRP; KCT0006997) approved the trial.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the Ministry of Education of the Republic of Korea, the National Research Foundation of Korea (NRF-2020S1A5B5A17090332) and Korea Breast Cancer Foundation (KBCF-2020U002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Presenter: Adam Brufsky
Session: Poster session 03
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Presenter: Jiayu Wang
Session: Poster session 03
405P - E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Presenter: Kan Yonemori
Session: Poster session 03
406P - Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Presenter: Sara Lopez-Tarruella Cobo
Session: Poster session 03
407P - Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Julia C. Radosa
Session: Poster session 03
408P - Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Presenter: Huiping Li
Session: Poster session 03
410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Presenter: Josephine Lemaitre
Session: Poster session 03
411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Presenter: Frederik Marmé
Session: Poster session 03
412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
Presenter: Alessandro Rizzo
Session: Poster session 03